These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 29785825)

  • 21. Conjunctival malignant melanoma with xeroderma pigmentosum.
    Aoyagi M; Morishima N; Yoshino Y; Imagawa N; Kiyosawa M; Ito M; Kondou S; Matsubara O
    Ophthalmologica; 1993; 206(3):162-7. PubMed ID: 8272340
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [GASTRIC MELANOMA METASTASES CAUSED BY XERODERMA PIGMENTOSUM].
    SARI A; LISKA J; JUDIN J
    Neoplasma; 1963; 10():641-50. PubMed ID: 14103650
    [No Abstract]   [Full Text] [Related]  

  • 23. Management of a young patient with xeroderma pigmentosum.
    Leal-Khouri S; Hruza GJ; Hruza LL; Martin AG
    Pediatr Dermatol; 1994 Mar; 11(1):72-5. PubMed ID: 8170856
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Xeroderma pigmentosum: neck lymph node metastasis of a squamous cell carcinoma of the skin treated with cetuximab.
    Rubió Casadevall J; Graña-Suárez B; Hernandez-Yagüe X; Vayreda Ribera J; Huc Grasa O; Brunet Vidal J
    Eur J Dermatol; 2009; 19(2):163-5. PubMed ID: 19106040
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clearing of melanoma in situ with intralesional interferon alfa in a patient with xeroderma pigmentosum.
    Turner ML; Moshell AN; Corbett DW; Stern JB; Roth MJ; DiGiovanna J; Horn TD; Kraemer KH
    Arch Dermatol; 1994 Dec; 130(12):1491-4. PubMed ID: 7986121
    [No Abstract]   [Full Text] [Related]  

  • 26. Multiloculated lentigo maligna melanoma in a patient without evidence for xeroderma pigmentosum.
    Brandt O; Abeck D; Weichenthal M; Steinkraus V; Breitbart E; Jung EG; Ring J
    Acta Derm Venereol; 1995 Jul; 75(4):326-7. PubMed ID: 8578964
    [No Abstract]   [Full Text] [Related]  

  • 27. Skin cancer developing in xeroderma pigmentosum patient relaxing sunlight avoidance.
    Lynch HT; Fusaro R; Edlund J; Albano W; Lynch J
    Lancet; 1981 Nov; 2(8257):1230. PubMed ID: 6118655
    [No Abstract]   [Full Text] [Related]  

  • 28. The safety of pembrolizumab in metastatic melanoma and rheumatoid arthritis.
    Puri A; Homsi J
    Melanoma Res; 2017 Oct; 27(5):519-523. PubMed ID: 28817445
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Xeroderma pigmentosum with multiple malignancies.
    Nalgirkar AR; Borkar SS; Nalgirkar SA
    Indian Pediatr; 2000 Dec; 37(12):1377-9. PubMed ID: 11119344
    [No Abstract]   [Full Text] [Related]  

  • 30. Malignant melanoma of the iris in xeroderma pigmentosum.
    Johnson MW; Skuta GL; Kincaid MC; Nelson CC; Wolter JR
    Arch Ophthalmol; 1989 Mar; 107(3):402-7. PubMed ID: 2923565
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Xeroderma pigmentosum complementation group G in association with malignant melanoma.
    Yoneda K; Moriue J; Matsuoka Y; Moriwaki S; Moriue T; Nakai K; Yokoi I; Nibu N; Demitsu T; Kubota Y
    Eur J Dermatol; 2007; 17(6):540-1. PubMed ID: 17951140
    [No Abstract]   [Full Text] [Related]  

  • 32. Lymphocytic gastritis induced by pembrolizumab in a patient with metastatic melanoma.
    Yip RHL; Lee LH; Schaeffer DF; Horst BA; Yang HM
    Melanoma Res; 2018 Dec; 28(6):645-647. PubMed ID: 30256271
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Image Gallery: Xeroderma pigmentosum.
    Partarrieu-Mejías F; Pérez-Velásquez F
    Br J Dermatol; 2016 Mar; 174(3):e12. PubMed ID: 27002581
    [No Abstract]   [Full Text] [Related]  

  • 34. Spontaneous regression of metastatic malignant melanoma in 2 sibs with xeroderma pigmentosum.
    Lynch HT; Frichot BC; Fisher J; Smith JL; Lynch JF
    J Med Genet; 1978 Oct; 15(5):357-62. PubMed ID: 739525
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma.
    Faghfuri E; Faramarzi MA; Nikfar S; Abdollahi M
    Expert Rev Anticancer Ther; 2015; 15(9):981-93. PubMed ID: 26313415
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Xeroderma pigmentosum. Complementation group C and malignant melanoma.
    Lynch HT; Fusaro RM; Johnson JA
    Arch Dermatol; 1984 Feb; 120(2):175-9. PubMed ID: 6696469
    [No Abstract]   [Full Text] [Related]  

  • 37. Collision of squamous-cell carcinoma with melanoma in situ in a child with xeroderma pigmentosum.
    Hofer A; Kaddu S; Seidl H; Kerl H; Wolf P
    Dermatology; 2001; 203(1):66-9. PubMed ID: 11549805
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ultraviolet damage, DNA repair and vitamin D in nonmelanoma skin cancer and in malignant melanoma: an update.
    Reichrath J; Rass K
    Adv Exp Med Biol; 2014; 810():208-33. PubMed ID: 25207368
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma.
    Longoria TC; Tewari KS
    Expert Opin Drug Metab Toxicol; 2016 Oct; 12(10):1247-53. PubMed ID: 27485741
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of matrix metalloproteinase-13 and Ki-67 in nonmelanoma skin cancer in xeroderma pigmentosum and non-xeroderma pigmentosum.
    El-Hawary AK; Yassin E; Khater A; Abdelgaber S
    Am J Dermatopathol; 2013 Feb; 35(1):45-9. PubMed ID: 22722466
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.